A novel MHC-associated Proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias

Leukemia

Volumn 20, Issue 6, 2006, Pages 1067-1072

  Knights, Ashley J ^a,f   Weinzierl, A O ^b   Flad, T ^a,d   Guinn, B A ^c   Mueller, L ^a,e   Mufti, G J ^c   Stevanovic, S ^b   Pawelec, G ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d PANATecs   (Germany)

^e GLYCOTOPE GMBH   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chronic myelogenous leukaemia; Peptide sequencing MHC ligands; Proteinase 3

Indexed keywords

BCR ABL PROTEIN; EPITOPE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELOBLASTIN; PEPTIDE; WT1 PROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL OBSERVATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 33744498890     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404234     Document Type: Article

References (21)

1. Mocellin S, Semenzato G, Mandruzzato S, Riccardo RC. Part II: Vaccines for haematological malignant disorders. Lancet Oncol 2004; 5: 727-737.
2. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
3. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681.
4. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-1023.
5. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887-2893.
6. Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood 1997; 90: 4938-4946.
7. Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1 (124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002; 51: 271-281.
8. Flad T, Spengler B, Kalbacher H, Brossart P, Baier D, Kaufmann R et al. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. Cancer Res 1998; 58: 5803-5811.
9. Kruger T, Schoor O, Lemmel C, Kraemer B, Reichle C, Dengjel J et al. Lessons to be learned from primary renal cell carcinomas: Novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005; 54: 826-836.
10. Posthuma EF, van Bergen CA, Kester MG, de Paus RA, van Veelen PA, de Ru AH et al. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 2004; 89: 1062-1071.
11. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
12. Hakansson P, Segal D, Lassen C, Gullberg U, Morse III HC, Fioretos T et al. Identification of genes differentially regulated by the P210 BCR/ ABL1 fusion oncogene using cDNA microarrays. Exp Hematol 2004; 32: 476-482.
13. Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y et al. MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene 2003; 22: 7774-7780.
14. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000; 83: 311-318.
15. Kellner R, Lichtenfels R, Atkins D, Bukur J, Ackermann A, Beck J et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002; 2: 1743-1751.
16. Hartmann TB, Thiel D, Dummer R, Schadendorf D, Eichmuller S. SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 2004; 150: 252-258.
17. Jager E, Nagata Y, Gnjatic S, Wada H, Stockert E, Karbach J et al. Monitoring CD8T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 4760-4765.
18. Abdelhaleem M. Do human RNA helicases have a role in cancer? Biochim Biophys Acta 2004; 1704: 37-46.
19. Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, Steele RJ et al. Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene 2001; 20: 7734-7743.
20. Miyaji K, Nakagawa Y, Matsumoto K, Yoshida H, Morikawa H, Hongou Y et al. Overexpression of a DEAD box/RNA helicase protein, rck/p54, in human hepatocytes from patients with hepatitis C virus-related chronic hepatitis and its implication in hepatocellular carcinogenesis. J Viral Hepat 2003; 10: 241-248.
21. Halder TM, Bluggel M, Heinzel S, Pawelec G, Meyer HE, Kalbacher H. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). Blood 2000; 95: 2890-2896.